Analyst Ranking
Top 16%
#758 out of 4928 analysts
Average Return
+27.31%
Win Rate
50%12 out of 24
Risk vs Reward
Poor
Good

Phil Nadeau's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Moonlake ImmunotherapeuticsMLTX
+740.17%$5.85$49.15
2022-07-06 -
2023-07-06
Buy
Immunomedics IncIMMU
+195.08%$7.72$22.78
2017-05-25 -
2018-05-25
Buy
Vertex Pharmaceuticals IncVRTX
+41.12%$358.40$505.78
2023-08-01 -
2024-08-01
Buy
Vertex Pharmaceuticals IncVRTX
+38.80%$245.39$340.60
2022-06-12 -
2023-06-12
Buy
Vertex Pharmaceuticals IncVRTX
+34.70%$350.78$472.51
2023-06-27 -
2024-06-27
Buy

Phil Nadeau Analyst Color

Get additional color on Phil Nadeau's coverage of popular stocks

Phil Nadeau's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Rhythm Pharmaceuticals IncRYTM
2Strong Buy$65.00-2.87%Maintains
8 months ago
Biogen IncBIIB
5Strong Buy$275.00+106.47%Maintains
8 months ago
Biomarin Pharmaceutical IncBMRN
1Strong Buy$120.00+109.90%Maintains
a year ago
Vertex Pharmaceuticals IncVRTX
7Strong Buy$500.00+9.40%Maintains
a year ago
Phasebio Pharmaceuticals IncPHASQ
1HoldN/AN/ADowngrades
3 years ago
Tricida IncTCDAQ
1HoldN/AN/ADowngrades
3 years ago
Moonlake ImmunotherapeuticsMLTX
1BuyN/AN/AInitiates Coverage On
3 years ago
Aura Biosciences IncAURA
1BuyN/AN/AInitiates Coverage On
4 years ago
Icosavax IncICVX
1BuyN/AN/AInitiates Coverage On
4 years ago
Lenz Therapeutics IncLENZ
1BuyN/AN/AInitiates Coverage On
4 years ago
Ambrx Biopharma IncAMAM
1BuyN/AN/AInitiates Coverage On
4 years ago
Annexon IncANNX
1BuyN/AN/AInitiates Coverage On
5 years ago
Akouos IncAKUS
1BuyN/AN/AInitiates Coverage On
5 years ago
Kezar Life Sciences IncKZR
1BuyN/AN/AInitiates Coverage On
7 years ago
Q32 Bio IncQTTB
1BuyN/AN/AInitiates Coverage On
7 years ago
Immunomedics IncIMMU
1Buy$15.00N/AInitiates Coverage On
8 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.